The file's text, extracted by GovTribe without its formatting.
STATEMENT OF WORK
Blood and Blood Products The VISN 8: Veterans Administration (VA) Sunshine Healthcare Network in Florida (hereinafter “VA” or “Government”), which includes: Bay Pines Healthcare System, North Florida/South Georgia Veterans Health System, Miami VA Healthcare System, Orlando VA Medical Center, James A. Haley Veterans’ Hospital, West Palm Beach VAMC and Caribbean VAMC has an ongoing requirement for the delivery of whole blood and blood products provided by an active Food and Drug Administration (FDA) registered or licensed blood bank entity, community(non-hospital) blood bank nonprofit corporation, accredited by AABB(American Association of Blood Banks), The College of American Pathologists (CAP), or the Joint Commission. The Contractor shall provide products, any other blood related services, and therapeutic services to attain a blood product that will be compatible and safe for a patient’s condition(s). These blood products shall be provided in accordance with the terms and conditions of this contract as stated in the Supplies/Services listing below.
SUPPLIES/SERVICES
Contractor shall supply each site with all Whole blood and blood components daily and maintain an emergency supply of each group, type of blood and blood components. Whole blood and blood products shall be furnished to multiple hospital facilities within Veterans Integrated Service Network (VISN 8), North Florida/South Georgia, and Caribbean locations, in accordance with the specifications of this contract. All quantities are estimated per annum.
BLOOD PRODUCTS ITEM LIST
BLOOD COMPONENTS -Unit of Issue (each)Estimated
| ITEM DESCRIPTION |
| Bay Pines |
| Gainesville |
| Miami |
| Orlando |
| San Juan |
| Tampa |
| West Palm |
| Total |
| 1 |
| Whole Blood Leukoreduced |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 2 |
| Whole Blood Leukoreduced Low Volume |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 3 |
| Whole Blood Leukoreduced Low Volume Irradiated |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 4 |
| Whole Blood Autologous Leukoreduced |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 5 |
| Red Blood Cells Leukoreduced |
| 2348 |
| 3338 |
| 1943 |
| 1500 |
| 2800 |
| 3991 |
| 2196 |
| 18116 |
| 6 |
| Red Blood Cells Leukoreduced Deglycerolized |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 7 |
| Red Blood Cells Leukoreduced Frozen |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 8 |
| Red Blood Cells Leukoreduced Irradiated |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 9 |
| Red Blood Cells Leukoreduced Low Volume |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 10 |
| Red Blood Cells Leukoreduced Washed |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 11 |
| Red Blood Cells Leukoreduced Deglycerolized Irradiated |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 12 |
| Red Blood Cells Leukoreduced Irradiated Washed |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 13 |
| Red Blood Cells Leukoreduced Processing - Infant (PediCells - CMV Neg.,) |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 14 |
| Red Blood Cells Autologous Leukoreduced |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 15 |
| Red Blood Cells Autologous Leukoreduced Deglycerolized |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 16 |
| Whole Blood Platelets Leukoreduced |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 17 |
| Platelet Pheresis Pedi-D |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 18 |
| Platelet Pheresis Pedi-W |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 19 |
| Cryoprecipitate |
| 1 |
| 1 |
| 1 |
| 50 |
| 250 |
| 1335 |
| 50 |
| 1688 |
| 20 |
| Pooled Cryoprecipitate (5) |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 21 |
| Pooled Cryoprecipitate (10) |
| 15 |
| 50 |
| 26 |
| 20 |
| 1 |
| 1 |
| 20 |
| 133 |
| 22 |
| Fresh Frozen Plasma |
| 423 |
| 306 |
| 595 |
| 300 |
| 850 |
| 944 |
| 300 |
| 3718 |
| 23 |
| Fresh Frozen Plasma Cryo-removed |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 24 |
| Fresh Frozen Plasma(0-24hr) |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 25 |
| Fresh Frozen Plasma - Infant Dose (Pediplasma Processing) |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 26 |
| Neo-Natal Fresh Frozen Plasma |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 27 |
| Plasma (Liquid) |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 28 |
| Plasma (Liquid) Irradiated |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 29 |
| Source Leukocyte |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 30 |
| Apheresis Platelets (SDP) Leukoreduced |
| 343 |
| 652 |
| 328 |
| 350 |
| 980 |
| 782 |
| 350 |
| 3785 |
| 31 |
| Apheresis Platelets (SDP) Leukoreduced Irradiated |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 32 |
| Apheresis Platelets (SDP) Leukoreduced Low Volume |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 33 |
| Apheresis Platelets (SDP)/LIW Leukoreduced Irradiated Washed |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 34 |
| Apheresis Platelets (SDP) Leukoreduced Low Volume Irradiated |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 35 |
| Apheresis Platelets (SDP) Autologous Leukoreduced Irradiated |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 36 |
| Apheresis Granulocytes |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 37 |
| Apheresis Granulocytes Irradiated |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 38 |
| Pooled Platelets Leukoreduced |
| 1 |
| 1 |
| 6 |
| 1 |
| 1 |
| 27 |
| 10 |
| 47 |
| 39 |
| Pooled Platelets Leukoreduced Irradiated |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
CELLULAR LAB- Unit of Issue (each)Estimated
| ITEM DESCRIPTION |
| Bay Pines |
| Gainesville |
| Miami |
| Orlando |
| San Juan |
| Tampa |
| West Palm |
| Total |
| 40 |
| SC ABO Incompatible Buffy Coat Enrichment |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 41 |
| SC Plasma Depletion |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 42 |
| SC Cryopreservation (includes 1st year storage) |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 43 |
| SC Colony Forming Unit (CFU) |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 44 |
| SC Stem Cell Quality Control |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 45 |
| SC Cord Wash Process |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 46 |
| SC Cord Blood Reconstitution |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 47 |
| Stem Cell Freight |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 48 |
| SC Thawing Frozen Cell (QC Vial each) |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 49 |
| SC CBC with automated differential |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 50 |
| SC CBC with manual differential |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 51 |
| CD34 Test |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 52 |
| SC Cellular Night and Weekend Fee |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 53 |
| SC Trypan Blue viability |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 54 |
| SC Storage greater than 1 year (storage per year) |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 55 |
| SC Sterility Check |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 56 |
| SC CD3 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 57 |
| SC CD4 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 58 |
| SC CD8 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 59 |
| SC Processing Split Exceeding 4 Bags (each) |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
Terms Defined SC= Sickle Cell CBC= Complete Blood Count SC Cryopreservation requires storage of product includes 1 year. Thereafter additional years of storage are charged separately CD- Cluster of differentiation
HLA AND SPECIAL HEMATOLOGY TESTING- Unit of Issue (each) Estimated
| Item Description |
| Bay Pines |
| Gainesville |
| Miami |
| Orlando |
| San Juan |
| Tampa |
| West Palm |
| Total |
| 60 |
| Platelet Crossmatch |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 61 |
| HLA/Platelet Antibody Screen (Serology/ELISA) |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 62 |
| HLA-Antibody Intermediate Resolution, Complex |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 63 |
| Neonate Allo- Thrombocytopenia Assessment |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 64 |
| Platelet Genotyping |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 65 |
| Platelet Auto Antibodies |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 66 |
| HLA ABC Typing (Class I) |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 67 |
| HLA DR/DQ Typing (Class II) |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 68 |
| HLA for Platelet Pheresis |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 69 |
| HLA-Antibody Intermediate Resolution, Basic |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 70 |
| RBC Genotype Bioarray (HEA) |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 71 |
| HLA - ABC/DR High Resolution, DQ Low Resolution |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 72 |
| Heparin Induced Thrombocytopenia Antibody (HIT) |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
Terms Defined HLA- Human Leukocyte Antigens HLA-DR Human Leukocyte Antigens related D
APHERESIS AND THERAPEUTIC SERVICES- Unit of Task Estimated
| Item Description |
| Bay Pines |
| Gainesville |
| Miami |
| Orlando |
| San Juan |
| Tampa |
| West Palm |
| Total |
| 73 |
| HPC Apheresis |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 74 |
| Photopheresis Procedure |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 75 |
| Therapeutic Cellular Depletion - WBC |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 76 |
| Therapeutic Phlebotomy (In Blood Center) |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 77 |
| Therapeutic phlebotomy - in hospital |
| 1 |
| 15 |
| 1 |
| 1 |
| 60 |
| 1 |
| 1 |
| 80 |
| 78 |
| Therapeutic phlebotomy with replacement fluid - in hospital |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 79 |
| Red Blood Cell Exchange |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 80 |
| Therapeutic Cellular Depletion - RBC |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 81 |
| Therapeutic Cellular Depletion - Platelet |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 82 |
| Therapeutic Plasma Exchange |
| 74 |
| 15 |
| 20 |
| 30 |
| 60 |
| 77 |
| 20 |
| 296 |
| 83 |
| Red Cell Prime |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
Terms defined:
HPC- hematopoietic progenitor cell WBC -White Blood Count RBC- Red Blood Count
REFERENCE TESTING- Unit of Issue (Task) Estimated
| Item Description |
| Bay Pines |
| Gainesville |
| Miami |
| Orlando |
| San Juan |
| Tampa |
| West Palm |
| Total |
| 84 |
| Radsure Label to be Irradiated |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 85 |
| Irradiation of unit |
| 38 |
| 1000 |
| 115 |
| 100 |
| 25 |
| 917 |
| 38 |
| 2233 |
| 86 |
| Deglycerolization of unit |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 87 |
| Freeze unit |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 88 |
| Freeze & Deglycerolization unit |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 89 |
| Pooling unit(s) |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 90 |
| Thaw unit |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 91 |
| RBC Wash |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 92 |
| Platelet Wash |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 93 |
| RBC Crossmatch (each additional unit) |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 94 |
| Non-crossmatch set up |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 95 |
| ABO Group |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 96 |
| RH Type |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 97 |
| Chemical Treatment |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 98 |
| Aliquot Bag |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 99 |
| Confirmatory Draw |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 100 |
| Platelet (Volume Reduction Fee) |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 101 |
| Computer Antigen Search (per Antigen) |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 102 |
| Patient Complete Phenotype, Serologic |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 103 |
| Reconstitute |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 104 |
| RBC Antibody Identification |
| 30 |
| 30 |
| 32 |
| 30 |
| 30 |
| 30 |
| 30 |
| 212 |
| 105 |
| Rare Unit |
| 5 |
| 5 |
| 20 |
| 5 |
| 5 |
| 5 |
| 5 |
| 50 |
| 106 |
| Antigen Typing - Single |
| 230 |
| 90 |
| 90 |
| 200 |
| 90 |
| 511 |
| 230 |
| 1441 |
| 107 |
| RBC Selected Cell Panel |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 108 |
| RBC Cell Separation |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 109 |
| IgG Dissociation |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 110 |
| Dithiotreitol Treatment |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 111 |
| Neutralization P1 or Lewis |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 112 |
| Chloroquine treatment |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 113 |
| Acid Elution / Cell Elution |
| 30 |
| 30 |
| 12 |
| 30 |
| 30 |
| 30 |
| 30 |
| 192 |
| 114 |
| Donath-Landsteiner Test |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 115 |
| Irradiation - Per Random Platelet |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 116 |
| Rare Donor Search thru American Rare Donor Program (ARDP) |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 117 |
| Splitting Service |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 118 |
| Type and Screen |
| 30 |
| 30 |
| 15 |
| 30 |
| 30 |
| 30 |
| 30 |
| 195 |
| 119 |
| ABO Group & Rh Type |
| 75 |
| 75 |
| 15 |
| 75 |
| 50 |
| 9 |
| 75 |
| 374 |
| 120 |
| Antibody Screen (Indirect Coombs) |
| 15 |
| 15 |
| 15 |
| 15 |
| 440 |
| 15 |
| 15 |
| 530 |
| 121 |
| RBC Antibody Titer |
| 1 |
| 1 |
| 7 |
| 1 |
| 1 |
| 1 |
| 1 |
| 13 |
| 122 |
| Direct Antiglobulin IgG (Direct Coombs) |
| 63 |
| 63 |
| 16 |
| 63 |
| 95 |
| 38 |
| 63 |
| 401 |
| 123 |
| Direct Antiglobulin DAT C3 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 124 |
| Fetal Screen |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 125 |
| Kleihauer - Betke |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 126 |
| CMV Test |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 127 |
| Sickle Cell Screen |
| 6 |
| 6 |
| 11 |
| 6 |
| 3 |
| 8 |
| 6 |
| 46 |
| 128 |
| LUI Elution |
| 1 |
| 1 |
| 1 |
| 1 |
| 15 |
| 1 |
| 1 |
| 22 |
| 129 |
| RBC Antibody Panel |
| 158 |
| 158 |
| 34 |
| 158 |
| 95 |
| 95 |
| 95 |
| 793 |
| 130 |
| Transfusion Reaction Work Up |
| 5 |
| 5 |
| 5 |
| 5 |
| 1 |
| 1 |
| 5 |
| 27 |
| 131 |
| RBC Antigen Typing |
| 32 |
| 32 |
| 394 |
| 32 |
| 208 |
| 90 |
| 32 |
| 820 |
| 132 |
| Adsorption |
| 32 |
| 32 |
| 95 |
| 32 |
| 32 |
| 32 |
| 32 |
| 287 |
| 133 |
| Cold Agglutinin Titer |
| 1 |
| 1 |
| 11 |
| 1 |
| 1 |
| 1 |
| 1 |
| 17 |
| 134 |
| ABO RH Cord |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 135 |
| Sterile Doc Quad Pack |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 136 |
| Enzyme Treatment |
| 2 |
| 2 |
| 11 |
| 2 |
| 63 |
| 11 |
| 2 |
| 93 |
| 137 |
| Lookback |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 138 |
| Crossmatch - Electronic |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
Terms Defined:
RBC- Red Blood Count ABO- Blood Types (group) CMV- Cytomegalovirus LUI- Technique for eluting antibodies from red cells
OTHER TESTING Unit of Issue (Task) - Estimated
| Item Description |
| Bay Pines |
| Gainesville |
| Miami |
| Orlando |
| San Juan |
| Tampa |
| West Palm |
| Total |
| 139 |
| NAT (HIV - I, HBV and HCV RNA) DONOR ONLY |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 140 |
| Non-Donor Infectious Disease Markers 3327 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 141 |
| Non-Donor Infectious Disease Markers 3486, no ABO/Rh |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 142 |
| White Blood Cell Counts by Flow Cytometry |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
| 143 |
| Cryoprecipitate QC |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| 7 |
Defined Terms:
NAT- Nucleic Acid Test QC- Quality Control ABO -Blood Type Rh- Blood group system RBC -Red Blood Group
SECTION I - WHOLE BLOOD AND BLOOD COMPONENTS
Whole blood and blood components, are to be delivered F.O.B. destination in packaging of protective quality that are suitable to maintain temperature for component transportation and ensure that component is undamaged during handling within consignee's premises, to each of the designated VISN 8 sites, for the period of the contract, in such quantities and at such times as may be required in accordance with all terms, conditions, provisions and the Schedule contained in this statement of work.
A. COLLECTION, PROCESS AND TYPING OF BLOOD
1. Blood shall be typed for Blood groups ABO and Rh antigens and screened for red cell antibodies in accordance with methods recommended in the current edition of Standards for Blood Banks and Transfusion Services and the Technical Manual of the American Association of Blood Banks (AABB). Blood shall be collected, processed, and stored in accordance with the Food and Drug Administration (FDA) Regulations (21CFR) and applicable contractor standard operating procedures under contractor’s US. License.
2. Contractor agrees that all components shipped will have been tested and found non-reactive for current testing requirements from the FDA and AABB Standards.
3. All blood and components are to be collected by a closed system under aseptic conditions and shall be processed in appropriate solutions and the containers labeled. The label shall also bear the expiration date of the contents. The expiration date shall not exceed 42 calendar days from the date of manufacture, which is the date of bleeding the donor, unless the type of preservative used is approved by the FDA for a longer interval.
4. All blood supplied shall be grossly free of hemolysis, excessive chyle and clots.
5. All blood must be leukocyte reduced.
6. Blood shall include at least ten (10) properly labeled and originally attached segments of the blood to be used in cross matching.
7. All platelets will be tested for bacterial contamination and pathogen reduction with manufacturer instruction using FDA approved instrumentation and AABB approved methods. AABB guidelines shall be followed for plasma components to reduce the risk of (Transfusion Related Acute Lung Injury) TRALI. Other screening will be performed on cellular components when requested and or required.
8. All plasma for allogeneic transfusion should be from males, females who have not been pregnant, or females who have been tested since the most recent pregnancy and results interpreted as Negative for HLA antibodies.
B. PACKAGING AND MARKING
1. Blood shall be labeled as to A, B, O, AB, and Rh type.
2. All blood components must use bar code labels (ISBT-128) conforming to International Council for Commonality in Blood Bank Automation, Inc. (ICCBBA) will be legible on all blood components.
3. Each shipment shall be properly packaged, labeled, and accompanied by an itemized shipping list in accordance with this solicitation. An authorized individual will sign for receipt of the blood.
4. Packaging shall be of protective quality to ensure that the product is undamaged during handling.
C. SPECIALIZED SERVICES
1. Contractor shall provide consultation services prior to delivery under the direction of the contractor’s Medical Director(s) to aid in the identification of difficult irregular antibodies, problem crossmatches and any such matters. Contractor shall provide Tissue TypiFng Services, Flow Cytometric Services, in house Therapeutic Apheresis Services, and other such services requested by the hospital. The contractor blood bank shall investigate all donors implicated in TRALI after notification by a VA site.
2. Reference laboratory services must be available twenty-four (24) hours per day, seven (7) days per week, and three-hundred and sixty-five (365) days per year including federal holidays.
3. The contractor blood bank provides reference laboratory services and esoteric components within one hour of receipt of specimen at their reference testing laboratory if ordered statim (STAT) or 4 hours if ordered as routine.
D. DELIVERIES AND PERFORMANCE
1. Blood products shall be delivered at the time specified when the order is placed. Routine stock orders are to be delivered within 12 hours of orders placement. In an emergency, contractor/courier service shall provide delivery within one (1) hour of request packed red blood cells to maintain an adequate blood supply and meet VA standard/regulations. Contractor shall deliver standard products at no extra charge (3) times a day, seven days a week.
2. Blood shall be transported in such a way as to ensure the integrity of blood components remain safe for use and not compromised. Contractor shall comply with all accreditation and regulatory standards as defined by the FDA and AABB.
3. Contractor shall provide all supplies necessary for shipment of blood components and specimens. Contractor shall provide any special preservatives for specimen preservation. Frozen specimens and components shall be shipped on dry ice provided by contractor.
4. Contractor shall provide a copy of their emergency Contingency Plan in Facilitating and coordinating an appropriate response in the event of a local domestic threat or disaster that affects the provision of a safe and adequate blood supply.
E. DELIVERY/TRANSPORTATION
1. The contractor shall provide deliveries of blood products twenty-four (24) hours per day, seven (7) days per week, three-hundred and sixty-five (365) days per year.
2. Contractor shall transport all requested blood and blood products to VA blood bank labs within the agreed upon timeframes.
The delivery locations are as follows:
1. C.W. Bill Young VA Medical Center Bay Pines VA Healthcare System Pathology & Laboratory Medicine Services (113) 10000 Bay Pines Blvd.
Building 100, Room 2B-111 (2nd Floor Lab) Bay Pines, Florida 33744
2. Malcolm Randall VAMC NF/SG Health System Pathology & Laboratory Medicine Services (113) 1601 S.W. Archer Road Gainesville, FL 32608 Blood Bank- Room E126 1st floor 352-374-6023
3. Miami VA Healthcare System Pathology & Laboratory Medicine Services (113) 1201 N.W. 16th Street Miami, FL 33125 Blood Bank- Room A305B 3rd floor 305-575-7000 ext. 4293/4294
4. Orlando VAMC Laboratory (113) 13800 Veterans Way Orlando, FL 32827 Blood Bank – D&T building 2nd floor Room 2J500 407-631-2606/07
5. VA Caribbean Healthcare System (113) Pathology and Laboratory Medicine Service 10 Casia Street San Juan, Puerto Rico 00921 Blood Bank- First Floor Room: A-116 787-641-2964
6. James A Haley Veterans Hospital Pathology & Laboratory Medicine Services (113) 13000 Bruce B. Downs Tampa, FL 33612 Blood Bank Lab- Room 1D-175 (1st floor) 813-972-2000ext4276
7. West Palm VAMC Laboratory (113) 7305 N Military Trail West Palm Beach, FL 33410 Room 4A203 inside of 4A201 561-422-6303
F. LICENSE: The contractor shall possess a current, unrevoked U.S. License which is issued by the Director, Bureau of Biologics, Food and Drug Administration (FDA) under Section 351 of the Public Health Service Act, as amended, 42 USC Section 262 (http://www.law.cornell.edu/uscode/text/42/262), as a source of supply for whole blood.
G. INTERSTATE SHIPMENT: If interstate shipment of blood or blood component is involved, the contractor must submit prior to award a statement that such approval has been authorized under Section 251 of the Public Health Service Act, as amended 42 USC Section 262.
H. CERTIFICATION: The contractor certifies that he/she complies and will remain in compliance with the requirements outlined with respect to donors, containers, and delivery of blood products for the duration of the contract.
I. BLOOD DONATION: The contractor shall provide the VA only with one hundred (100%) "volunteer donor" blood in accordance with CFR Title 21, Chapter I, Subchapter F, Part 606, Subpart G, Section §606.121(c)(8)(v)(B) where a volunteer donor is a person who does not receive monetary payment for blood donation. Definition of a "volunteer donor" - A volunteer donor is a person who does not receive monetary payment for blood donation. Benefits, such as monetary time off from work, membership in blood assurance programs and cancellations on non-replacement fees that are not readily convertible to cash, do not constitute monetary payment.
J. DONOR LIST:
1. The contractor shall maintain readily available blood donor lists including names, addresses, and social security numbers. Such lists should indicate on what date blood of a particular donor was furnished to the VA under this contract period.
2. Donor selection must be in accordance with criteria established by the FDA and/or the AABB.
K. AUTOLOGOUS COLLECTION AND UNITS:
Autologous blood units shall be tested for infectious agents per FDA and AABB regulations. Contractor will draw, test and return autologous unit with provider order and contractor director approval.
L. ORDERING:
1. Orders shall be categorized into two (2) types: routine and STAT. These categories are defined as follows:
a. Routine – Shipments of blood products to maintain minimum inventory levels or blood products ordered to fulfill a standing request.
b. STAT – A need for blood products so acute that a patient’s life could be jeopardized if the request for blood products is unfulfilled. STAT orders must be delivered within sixty (60) minutes. Additional emergency requirements may be placed and the shipper shall arrange for delivery in one hour or less (including orders during evenings and nights).
c. Ordering shall be conducted in accordance with applicable laws and resulting contract. Supplies and/or services may be ordered via email, facsimile (fax), telephone, in hardcopy format, electronic means including vendor websites or in any other manner consistent with accepted commercial business practices. No sensitive data will be transmitted.
M. INSPECTION OF CONTRACTOR’S FACILITIES:
The government reserves the right to thoroughly inspect and investigate the establishment, and facilities and verify other qualifications of any contractor.
N. NOTIFICATION AND REPORTING REQUIREMENTS:
In accordance with 21 CFR 610.46, 610.47 & 610.48, VA transfusion service shall be notified of any subsequent positive viral donor test results discovered by contractor after delivery. Contractor shall contact affected VA within 3 calendar days if supplied blood and blood components collected from a donor who tested negative at the time of donation but tests reactive for evidence of HIV or HCV.
SECTION II – THERAPEUTICS APHERISIS SERVICES
The contractor agrees to provide inpatient and outpatient therapeutic apheresis procedure. Procedures must be available seven days a week and must be provided within a 24-hour period of request for regularly scheduled cases. Emergency/STAT response time shall be within 4 hours once a patient and products are ready. The contractor warrants that all therapeutic apheresis services shall be provided by qualified and experienced personnel who shall be Registered Nurses or Licensed Practical Nurses. Contractor shall provide evidence of all education, professional licenses and or certifications, training, competency assessments and performance evaluations of all nursing staff utilized to perform these procedures. For purposes of this contract, all such personnel shall hereinafter be referred to as "Apheresis Nurses".
The contractor shall provide all equipment and disposables necessary to accomplish therapeutic apheresis procedures once vascular access has been established by VA personnel, and comply with the federal, state and local regulations for disposal of such supplies and waste products. It is preferable that contractor utilizes portable equipment that will allow the Apheresis Nurses to perform therapeutic procedures at the patient’s bedside. Contractor will provide documentation of the therapeutic procedure when completed to VA staff to be included into the patient’s medical record.
Contractor shall provide all maintenance and service records on equipment that will be used to perform these procedures. Contractor is responsible in ensuring that equipment maintenance is kept up to date and complies with manufacturer instructions. Contractor must ensure that all equipment is safe for usage and provide evidence of staff training and competency on equipment.
SECTION III - REFERENCE TESTING
The contractor shall provide highly specialized testing for all levels of transfusion testing needed to help determine which type of blood component is compatible and suitable for patients with rare blood types, or for patients who exhibit an unusual combination of antibodies against certain blood components. Contractor shall resolve complex antibody identification problems, help select compatible donors and perform genetic screening for blood group and platelet antigen.
SECTION IV – OTHER CONDITIONS
A. THE JOINT COMMISSION, VETERANS HEALTH ADMINISTRATION (VHA) AND OTHER STANDARDS:
1. The contractor shall perform the required work in accordance with The Joint Commission, OSHA, VHA HIPAA, FDA, AABB and/or any other regulatory standards. The contractor shall comply with all annual updates as issued.
2. Contractor shall maintain the minimum acceptable service, reporting systems and quality control as specified herein. Failure to comply with the specified terms and conditions and/or adverse reports from external monitoring agencies, which indicate poor quality of care or/and any other noncompliance issues, are grounds for termination of the contract. Immediate notification (within 24 hours shall be given to VA regarding adverse reports and action by a regulatory agency.
3. The requirements of the contract may be changed by written modification and agreement of the parties. All modifications will be approved and prepared by the VA Contracting Officer.
4. The contractor shall furnish the supplies specified in this contract to VA when authorized by the Contracting Officer Representative (COR).
B. TERM OF CONTRACT:
1. This contract is for one base period with four option years.
2. The contractor is required to begin providing supplies and services in accordance with the schedule, effective on the date of contract award.
C. QUALIFICATIONS:
1. The contractor shall have a blood bank currently registered and/or licensed with the Food and Drug Administration (FDA), Department of Health, Education and Welfare pursuant to Section 510 of the Federal Food, Drug and Cosmetic Act, 21 USC Section 301. Contractor’s Medical Director shall be a board-certified physician in Clinical Pathology/Blood Bank Transfusion Medicine. The government will only enter a legally binding contract with contractors who are regularly established in the business called for and who, in the judgment of the Contracting Officer, are financially responsible and able to show evidence of their responsibility, ability, experience, equipment, facilities, and personnel directly employed or supervised by them to render prompt and satisfactory supplies in the volume required for all items under this contract. By the signing the contract, the contractor is certifying that he/she shall meet all requirements of Federal, State, or local laws, codes, and/or regulations regarding the operation of this type of business.
2. The VA may inspect the establishment, facilities, business reputation, and other qualifications of any contractor and reserves the right to reject any offer, irrespective of price, that shall be administratively determined by the Contracting Officer to be lacking in any of the essentials judged necessary to assure acceptable standards of performance.
3. Any sub-contractor utilized by the contractor for the provision of supplies required under this contract must meet the same qualifications specified herein for the contractor. The contractor must obtain approval from the Contracting Officer for any sub-contractor to be utilized for the provision of supplies required under this contract.
4. Thirty (30) days prior to contract expiration date, the contractor shall certify in writing to the Contracting Officer that all licenses and registrations of personnel employed under this contract are valid and current and shall be renewed as necessary during any option period.
D. PERSONNEL POLICY:
The Contractor shall assume full responsibility for the protection of its personnel furnishing services under this contract, in accordance with the personnel policy of the Contractor, such as providing worker’s compensation, professional liability insurance, health examinations, income tax withholding, and social security payments. The parties agree that the contractor, its employees, agents, and subcontractors shall not be considered VA employees for any purpose.
E. CONFIDENTIALITY:
1. The VA will provide the contractor with access to pertinent patient medical information, within the existing privacy rules and regulations. Contractor shall ensure the confidentiality of all patient information and shall be held liable in the event of the breach of confidentiality.
2. The contract is subject to the Privacy Act of 1974. The Contractor is not authorized to release any VA medical record information. The VA is the sole entity authorized to release this information upon written request from the patient.
F. PAYMENTS, INVOICING AND CREDIT:
1. Charges should be inclusive of all transportation charges as defined in Deliveries and Performance, except those charges incurred and authorized by Pathology & Laboratory Medicine Service.
2. There will be no additional fees for autologous donations for transfusions at VA Health Care System (HCS).
3. All unsatisfactory units (broken Fresh Frozen Plasma (FFP), clots in red cells, etc.) shall be returned and full credit given to VA.
4. Full credit will be provided for returned units. Full credit shall be provided for blood products returned 24 hours prior to expiration date.
5. All invoices will be paid monthly in arrears upon receipt and certification of invoice. Each invoice must indicate the month in which the items were delivered and the appropriate obligation number.
6. GOVERNMENT INVOICE ADDRESS: All Invoices from the contractor shall be submitted electronically in accordance with VAAR Clause 852.232-72 Electronic Submission of Payment Requests.
7. Invoices shall be matched against VA bill validation report to verify supplies were delivered in accordance with the contract.
8. The VA will review the invoice against its record. VA will notify the contractor of invoice discrepancies. Upon the resolution of the discrepancies, contractor shall submit a revised invoice; the VA will verify revised invoice and make payment accordingly.
G. OTHER/APPLICABLE POLICIES AND REGULATIONS:
The Contractor shall perform in accordance with policies and procedures set forth in VHA Handbook 1106.01, Pathology and Laboratory Medicine Service Procedures the handbook can be located at the following web address: www.va.gov/vhapublications/viewpublication.asp?pub_id=1779
| United Stated Department of Health and Human Service (HHS)/Office of Inspector General (OIG): To ensure that the individuals performing under the contract have not engaged in fraud or abuse regarding Sections 1128 and 1128A of the Social Security Act regarding federal health care programs, the contractor is required to check the Health and Human Service – Office of Inspector General, List of excluded individuals/entities on the OIG Website (www.hhs.gov/oig) for each person providing services under this contract. Further the contractor is required to certify in its proposal that all persons listed in the contractor’s proposal have been compared against the OIG list and are not listed. During the performance of this contract the Contractor is prohibited from using any individual or business listed on the List of Excluded Individuals/Entities. |
| “Contractor shall provide health care to patients seeking such care from or through VA. As such, contractor is considered part of the Department health activity for purposes of the following statues and the VA regulations implementing these statues: the Privacy Act, 5.U.S.C. § 552a, and 38 U.S.C. §s 5701, 7705 and 7332. Contractor and its employees may have access to VA patient medical records to the extent necessary for the contract or to perform this contract. Notwithstanding any other provision of this contract, contractor and its employees shall disclose patient treatment records only pursuant to explicit disclosure authority for VA. Contractor and its employees are subject to the penalties and liabilities provided statutes and regulations for unauthorized disclosures of such records and their contents.” “Records created by the contractor in the course of treating VA patients under this agreement are the property of the VA and shall not be accessed, released, transferred or destroyed except in accordance with applicable federal law and regulations.” “Upon the expiration of this contract or termination of the contract, the contractor shall promptly provide the VA with the VA patient treatment records.” |
| HIPAA COMPLIANCE: “Contractor must adhere to the provisions of Public Law 104-191, Health Insurance Portability and Accountability Act (HIPAA) of 1996 and the National Standards to Protect the Privacy and Security of Protected Health Information (PHI). A business associate agreement is not required in this case. |
H. CONTRACTING OFFICER REPRESENTATIVE (COR):
All work coordination shall be made through the COR. The Contractor shall be provided a copy of the letter of delegation, authorizing the COR at the commencement of the term of this agreement. No other person shall be authorized to act in such capacity unless appointed in writing by the Contracting Officer. The COR will be the VA official responsible for verifying contract compliance. After contract award, any incidents of contractor noncompliance as evidenced by the monitoring procedures shall be forwarded immediately to the Contracting Officer.
I. SERVICES CHARGES TO VA BENEFICIARIES:
VA beneficiaries shall not under any circumstances be charged nor their insurance companies charged for services rendered by the contractor even if VA does not pay for those services. This provision shall survive the termination or ending of the contract
J. REQUIRED REGISTRATION WITH CONTRACTOR PERFORMANCE ASSESSMENT SYSTEM (CPARS):
1. As prescribed in Federal Acquisition Regulation (FAR) Part 42.15, the VA evaluates contractor past performance on all contracts that exceed $100,000, and shares those evaluations with other Federal Government contract specialists and procurement officials. The FAR requires that the contractor be provided an opportunity to comment on past performance evaluations prior to each report closing. To fulfill this requirement VA uses an online database, CPARS, which is maintained by the Naval Seal Logistics Center in Portsmouth, Virginia. CPARS has connectivity with the Past Performance Information Retrieval System (PPIRS) database, which is available to all Federal agencies. PPIRS is the system used to collect and retrieve performance assessment reports used in source selection determinations and completed CPARS report cards transferred to PPIRS. CPARS also includes access to the federal awardees performance and integrity information system (FAPIIS). FAPIIS is a web-enabled application accessed via CPARS for contractor responsibility determination information. REVIEW
2. Each contractor whose contract award is estimated to exceed $100,000 is required to register with CPARS database at the following web address: www.cpars.csd.disa.mil. Help in registering can be obtained by contacting Customer Support Desk @ DSN: 684-1690 or COMM: 207-438-1690. Registration shall occur no later than thirty days after contract award, and it shall be kept current in the case that any change to the contractor’s registered representative occurs.
3. For contracts with a period of one year or less, the contracting officer will perform a single evaluation when the contract is complete. For contracts exceeding one year, the contracting officer will evaluate the contractor’s performance annually. Interim reports will be filed each year until the last year of the contract, when the final report will be completed. The report shall be assigned in CPARS to the contractor’s designated representative for comment. The contractor representative will have thirty days to submit any comments and re-assign the report to the VA contracting officer.
4. Failure to have a current registration in the CPARS database, or to re-assign the report to the VA contracting officer within those thirty days, will result in the Government’s evaluation being placed on file in the database with a statement that the contractor failed to respond.
K. DOCUMENTING PERFORMANCE:
1. ACCEPTABLE PERFORMANCE
The Government will document acceptable as well as unacceptable performance. Any report may become a part of the supporting documentation for any contractual action.
2. UNACCEPTABLE PERFORMANCE
When unacceptable performance occurs, the Contractor Officer Representative (COR) will inform the contractor. This will normally be in writing unless circumstances necessitate verbal communication. In any case the COR will document the discussion and place it in the COR file.
When the COR determines, formal written communication is required, the COR will prepare a Contract Discrepancy Report (CDR), and present it to the contractor's program manager.
The contractor shall acknowledge receipt of the CDR in writing. The CDR will specify if the contractor is required to prepare a corrective action plan to document how the contractor shall correct the unacceptable performance and avoid a recurrence. The CDR will also state how long after receipt the contractor has to present this corrective action plan to the COR. The Government will review the contractor's corrective action plan to determine acceptability.
Any CDRs may become a part of the supporting documentation for any contractual action deemed necessary by the CO.
L. FREQUENCY OF MEASUREMENT:
1. Frequency of Measurement.
During contract performance, the COR will periodically analyze whether the negotiated frequency of surveillance is appropriate for the work being performed.
2. Frequency of Performance Assessment Meetings.
The COR will meet with the contractor monthly to assess performance and will provide a written assessment for the Contractor and Contracting Officer.
SECTION V- DEFINITIONS
F.O.B- An abbreviation for free on board, which means that a vendor or consignor will deliver goods on a railroad car, truck, vessel, or other conveyance without any expense to the purchaser or consignee.
Rh- Rhesus (Rh) factor is an inherited protein found on the surface of red blood cells Consignee- deliver (something) to a person's custody; send (goods) by a public carrier. A party (usually a buyer) named by the consignor (usually a seller) in transportation documents as the party to whose order a consignment will be delivered at the port of destination.
AABB- International non-profit association representing individuals and institutions involved in the field of transfusion medicine and cellular therapies. AABB has been a leader in the development of voluntary standards in blood bank blood component collection, processing, and transfusion.
ICCBBA- Enhances safety for patients by managing and promoting the ISBT 128 international information standard for use in transfusion and transplantation.
CFR- Code of Federal Regulations Apheresis- Is a medical technology in which the blood of a person is passed through an apparatus that separates out one constituent and returns the remainder to the circulation Apheresis Nurses- The Apheresis nurse performs all aspects of apheresis collection, using the centrifuge machines. The nurse monitors the machine and monitors the donor for possible reactions. The Apheresis RN will operate and manage several different apheresis blood cell separators, conduct donor medical history review and perform physical assessments to determine donor eligibility for bone marrow transplantation. The Apheresis RN will have direct patient care and be responsible for performing routine nursing functions while patients are undergoing an apheresis treatment.
TRALI Transfusion- Related acute lung injury (TRALI) is defined as new acute lung injury (ALI) that occurs during or within six hours of transfusion, not explained by another ALI risk factor.
HLA- The human leukocyte antigen (HLA) system is a gene complex encoding the major histocompatibility complex (MHC) proteins in humans. These cell-surface proteins are responsible for the regulation of the immune system in humans.
STATIM- Immediately or without delay.
